ENDOMETRIAL NEOPLASMS
Clinical trials for ENDOMETRIAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL NEOPLASMS trials appear
Sign up with your email to follow new studies for ENDOMETRIAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Smart Bomb' drug targets multiple advanced cancers
Disease control OngoingThis study is testing an experimental drug called disitamab vedotin in people with advanced or metastatic cancers that have spread and express a marker called HER2. The trial includes 120 adults with head and neck, lung, ovarian, or endometrial cancer who have already tried other…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo tested for Tough-to-Treat cancers
Disease control OngoingThis study is testing a new drug called E7386, given in combination with other cancer medications, for people with advanced solid tumors including endometrial, liver, and colorectal cancers. The main goals are to find the safest and most effective dose and to see how well the com…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New cancer drug enters first human trials for multiple tumor types
Disease control OngoingThis is the first human study testing the safety and early effects of an experimental drug called BL-M17D1 in people with advanced cancers that have a specific marker called HER2. The trial will enroll 120 adults with various hard-to-treat cancers, including breast, lung, and sto…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Major trial tests promising new combo for Tough-to-Treat uterine cancer
Disease control OngoingThis study is testing whether adding two newer drugs, durvalumab and olaparib, to standard chemotherapy helps women with advanced or recurrent endometrial cancer live longer without their cancer getting worse. It involves about 805 women who have not yet received treatment for th…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC